FATE THERAPEUTICS INC Net Income
FATE THERAPEUTICS INC (FATE) reported Net Income of -$30.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-13
- FATE THERAPEUTICS INC net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$30.16M.
- FATE THERAPEUTICS INC net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$31.21M.
- FATE THERAPEUTICS INC net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$32.37M.
- FATE THERAPEUTICS INC net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$32.25M.
- FATE THERAPEUTICS INC net income (loss) attributable to parent for fiscal 2022 was -$281.72M.
- FATE THERAPEUTICS INC net income (loss) attributable to parent for fiscal 2021 was -$212.15M.
- FATE THERAPEUTICS INC net income (loss) attributable to parent for fiscal 2020 was -$173.39M.
- FATE THERAPEUTICS INC net income (loss) attributable to parent for fiscal 2019 was -$98.15M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 8 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 77 month | Net Income (Loss) Attributable to Parent 80 month | Net Income (Loss) Attributable to Parent 83 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$30.16M 10-Q · filed 2026-08-13 | -$61.37M 10-Q · filed 2026-08-13 | -$93.75M derived: sum of 3 quarters · filed 2026-08-13 | -$126.00M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$31.21M 10-Q · filed 2026-08-13 | -$63.59M derived: sum of 2 quarters · filed 2026-08-13 | -$95.84M derived: sum of 3 quarters · filed 2026-08-13 | -$129.91M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$32.37M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | -$64.62M derived: sum of 2 quarters · filed 2026-04-24 | -$98.69M derived: sum of 3 quarters · filed 2026-08-13 | -$136.31M DEF 14A · filed 2026-04-24 | ||||
| 2025-09-30 | -$32.25M 10-Q · filed 2025-11-13 | -$66.32M derived: sum of 2 quarters · filed 2026-08-13 | -$103.94M 10-Q · filed 2025-11-13 | -$156.09M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$34.07M 10-Q · filed 2026-08-13 | -$71.69M 10-Q · filed 2026-08-13 | -$123.84M derived: sum of 3 quarters · filed 2026-08-13 | -$171.52M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$37.62M 10-Q · filed 2026-08-13 | -$89.77M derived: sum of 2 quarters · filed 2026-08-13 | -$137.45M derived: sum of 3 quarters · filed 2026-08-13 | -$175.88M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2024-12-31 | -$52.15M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | -$99.83M derived: sum of 2 quarters · filed 2026-04-24 | -$138.26M derived: sum of 3 quarters · filed 2026-04-24 | -$186.26M DEF 14A · filed 2026-04-24 | ||||
| 2024-09-30 | -$47.68M 10-Q · filed 2025-11-13 | -$86.11M derived: sum of 2 quarters · filed 2025-11-13 | -$134.11M 10-Q · filed 2025-11-13 | -$178.23M derived: sum of 4 quarters · filed 2026-04-24 | ||||
| 2024-06-30 | -$38.43M 10-Q · filed 2025-11-13 | -$86.43M 10-Q · filed 2025-08-12 | -$130.55M derived: sum of 3 quarters · filed 2026-04-24 | -$175.72M derived: sum of 4 quarters · filed 2026-04-24 | ||||
| 2024-03-31 | -$48.00M 10-Q · filed 2025-11-13 | -$92.13M derived: sum of 2 quarters · filed 2026-04-24 | -$137.30M derived: sum of 3 quarters · filed 2026-04-24 | -$190.05M derived: sum of 4 quarters · filed 2026-04-24 | ||||
| 2023-12-31 | -$44.12M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | -$89.29M derived: sum of 2 quarters · filed 2026-04-24 | -$142.05M derived: sum of 3 quarters · filed 2026-04-24 | -$160.93M DEF 14A · filed 2026-04-24 | ||||
| 2023-09-30 | -$45.17M 10-Q · filed 2024-11-12 | -$97.92M derived: sum of 2 quarters · filed 2024-11-12 | -$116.81M 10-Q · filed 2024-11-12 | -$173.17M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | -$52.76M 10-Q · filed 2024-11-12 | -$71.64M 10-Q · filed 2024-08-13 | -$128.00M derived: sum of 3 quarters · filed 2024-11-12 | -$211.56M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-03-31 | -$18.88M 10-Q · filed 2024-11-12 | -$75.24M derived: sum of 2 quarters · filed 2024-11-12 | -$158.81M derived: sum of 3 quarters · filed 2024-11-12 | -$234.91M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2022-12-31 | -$56.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$139.93M derived: sum of 2 quarters · filed 2024-02-26 | -$216.03M derived: sum of 3 quarters · filed 2024-02-26 | -$281.72M 10-K · filed 2024-02-26 | ||||
| 2022-09-30 | -$83.56M 10-Q · filed 2023-11-08 | -$159.67M derived: sum of 2 quarters · filed 2023-11-08 | -$225.36M 10-Q · filed 2023-11-08 | -$293.98M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | -$76.11M 10-Q · filed 2023-11-08 | -$141.79M 10-Q · filed 2023-08-08 | -$210.42M derived: sum of 3 quarters · filed 2023-11-08 | -$253.72M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-03-31 | -$65.69M 10-Q · filed 2023-11-08 | -$134.31M derived: sum of 2 quarters · filed 2023-11-08 | -$177.62M derived: sum of 3 quarters · filed 2023-11-08 | -$232.75M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2021-12-31 | -$68.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$111.93M derived: sum of 2 quarters · filed 2023-02-28 | -$167.06M derived: sum of 3 quarters · filed 2023-02-28 | -$212.15M 10-K · filed 2023-02-28 | ||||
| 2021-09-30 | -$43.31M 10-Q · filed 2022-11-03 | -$98.44M derived: sum of 2 quarters · filed 2022-11-03 | -$143.53M 10-Q · filed 2022-11-03 | -$196.64M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | -$55.13M 10-Q · filed 2022-11-03 | -$100.22M 10-Q · filed 2022-08-03 | -$153.33M derived: sum of 3 quarters · filed 2023-02-28 | -$212.02M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | -$45.09M 10-Q · filed 2022-11-03 | -$98.20M derived: sum of 2 quarters · filed 2023-02-28 | -$156.88M derived: sum of 3 quarters · filed 2023-02-28 | -$184.96M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | -$53.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$111.80M derived: sum of 2 quarters · filed 2023-02-28 | -$139.87M derived: sum of 3 quarters · filed 2023-02-28 | -$173.39M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | -$58.68M 10-Q · filed 2021-11-04 | -$86.76M derived: sum of 2 quarters · filed 2021-11-04 | -$120.28M 10-Q · filed 2021-11-04 | -$148.58M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | -$28.07M 10-Q · filed 2021-11-04 | -$61.59M 10-Q · filed 2021-08-04 | -$89.89M derived: sum of 3 quarters · filed 2021-11-04 | -$116.50M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-03-31 | -$33.52M 10-Q · filed 2021-11-04 | -$61.82M derived: sum of 2 quarters · filed 2021-11-04 | -$88.43M derived: sum of 3 quarters · filed 2021-11-04 | -$111.91M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2019-12-31 | -$28.30M 10-K · filed 2020-03-02 | -$54.91M derived: sum of 2 quarters · filed 2020-11-05 | -$78.39M derived: sum of 3 quarters · filed 2020-11-05 | -$98.15M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | -$26.61M 10-Q · filed 2020-11-05 | -$50.09M derived: sum of 2 quarters · filed 2020-11-05 | -$69.85M 10-Q · filed 2020-11-05 | -$85.87M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | -$23.48M 10-Q · filed 2020-11-05 | -$43.24M 10-Q · filed 2020-08-05 | -$59.27M derived: sum of 3 quarters · filed 2020-11-05 | -$76.05M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-03-31 | -$19.76M 10-Q · filed 2020-11-05 | -$35.79M derived: sum of 2 quarters · filed 2020-11-05 | -$52.57M derived: sum of 3 quarters · filed 2020-11-05 | -$72.22M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2018-12-31 | -$16.03M 10-K · filed 2020-03-02 | -$32.81M derived: sum of 2 quarters · filed 2020-03-02 | -$52.46M derived: sum of 3 quarters · filed 2020-03-02 | -$66.60M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | -$16.78M 10-K · filed 2020-03-02 | -$36.44M derived: sum of 2 quarters · filed 2020-03-02 | -$50.57M 10-Q · filed 2019-11-05 | -$63.07M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | -$19.65M 10-K · filed 2020-03-02 | -$33.79M 10-Q · filed 2019-08-06 | -$46.29M derived: sum of 3 quarters · filed 2020-03-02 | -$56.97M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | -$14.13M 10-K · filed 2020-03-02 | -$26.63M derived: sum of 2 quarters · filed 2020-03-02 | -$37.32M derived: sum of 3 quarters · filed 2020-03-02 | -$46.96M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | -$12.50M 10-K · filed 2019-03-05 | -$23.18M derived: sum of 2 quarters · filed 2019-03-05 | -$32.83M derived: sum of 3 quarters · filed 2019-03-05 | -$42.95M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | -$10.68M 10-K · filed 2019-03-05 | -$20.33M derived: sum of 2 quarters · filed 2019-03-05 | -$30.45M 10-Q · filed 2018-11-01 | -$38.40M derived: sum of 4 quarters · filed 2019-03-05 | ||||
| 2017-06-30 | -$9.64M 10-K · filed 2019-03-05 | -$19.77M 10-Q · filed 2018-08-06 | -$27.71M derived: sum of 3 quarters · filed 2019-03-05 | -$36.45M derived: sum of 4 quarters · filed 2019-03-05 | ||||
| 2017-03-31 | -$10.13M 10-K · filed 2019-03-05 | -$18.07M derived: sum of 2 quarters · filed 2019-03-05 | -$26.80M derived: sum of 3 quarters · filed 2019-03-05 | -$35.21M derived: sum of 4 quarters · filed 2019-03-05 | ||||
| 2016-12-31 | -$7.94M 10-K · filed 2018-03-05 | -$16.68M derived: sum of 2 quarters · filed 2018-03-05 | -$25.09M derived: sum of 3 quarters · filed 2018-03-05 | -$33.46M 10-K · filed 2019-03-05 | ||||
| 2016-09-30 | -$8.74M 10-K · filed 2018-03-05 | -$17.14M derived: sum of 2 quarters · filed 2018-03-05 | -$25.52M 10-Q · filed 2017-11-01 | -$32.97M derived: sum of 4 quarters · filed 2018-03-05 | ||||
| 2016-06-30 | -$8.41M 10-K · filed 2018-03-05 | -$16.79M 10-Q · filed 2017-08-14 | -$24.23M derived: sum of 3 quarters · filed 2018-03-05 | -$31.12M derived: sum of 4 quarters · filed 2018-03-05 | ||||
| 2016-03-31 | -$8.38M 10-K · filed 2018-03-05 | -$15.82M derived: sum of 2 quarters · filed 2018-03-05 | -$22.71M derived: sum of 3 quarters · filed 2018-03-05 | -$30.49M derived: sum of 4 quarters · filed 2018-03-05 | ||||
| 2015-12-31 | -$7.45M 10-K · filed 2017-03-16 | -$14.33M derived: sum of 2 quarters · filed 2017-03-16 | -$22.11M derived: sum of 3 quarters · filed 2017-03-16 | -$29.99M 10-K · filed 2018-03-05 | ||||
| 2015-09-30 | -$6.89M 10-K · filed 2017-03-16 | -$14.66M derived: sum of 2 quarters · filed 2017-03-16 | -$22.55M 10-Q · filed 2016-11-07 | -$28.78M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | -$7.78M 10-K · filed 2017-03-16 | -$15.66M 10-Q · filed 2016-08-08 | -$21.89M derived: sum of 3 quarters · filed 2017-03-16 | -$28.50M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | -$7.88M 10-K · filed 2017-03-16 | -$14.11M derived: sum of 2 quarters · filed 2017-03-16 | -$20.72M derived: sum of 3 quarters · filed 2017-03-16 | -$26.78M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2014-12-31 | -$6.23M 10-K · filed 2016-03-03 | -$12.84M derived: sum of 2 quarters · filed 2016-03-03 | -$18.90M derived: sum of 3 quarters · filed 2016-03-03 | -$25.88M 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | -$6.60M 10-K · filed 2016-03-03 | -$12.67M derived: sum of 2 quarters · filed 2016-03-03 | -$19.65M 10-Q · filed 2015-11-03 | -$25.39M derived: sum of 4 quarters · filed 2016-03-03 | ||||
| 2014-06-30 | -$6.07M 10-K · filed 2016-03-03 | -$13.05M 10-Q · filed 2015-08-05 | -$18.79M derived: sum of 3 quarters · filed 2016-03-03 | -$24.86M derived: sum of 4 quarters · filed 2016-03-03 | ||||
| 2014-03-31 | -$6.98M 10-K · filed 2016-03-03 | -$12.72M derived: sum of 2 quarters · filed 2016-03-03 | -$18.79M derived: sum of 3 quarters · filed 2016-03-03 | -$24.33M derived: sum of 4 quarters · filed 2016-03-03 | -$93.49M 10-Q · filed 2014-05-13 | |||
| 2013-12-31 | -$5.74M 10-K · filed 2015-03-12 | -$11.81M derived: sum of 2 quarters · filed 2015-03-12 | -$17.35M derived: sum of 3 quarters · filed 2015-03-12 | -$20.89M 10-K · filed 2016-03-03 | -$86.51M 10-K · filed 2014-03-17 | |||
| 2013-09-30 | -$6.07M 10-K · filed 2015-03-12 | -$11.61M derived: sum of 2 quarters · filed 2015-03-12 | -$15.15M 10-Q · filed 2014-11-12 | -$19.31M derived: sum of 4 quarters · filed 2015-03-12 | -$80.77M 10-Q · filed 2013-11-13 | |||
| 2013-06-30 | -$5.53M 10-K · filed 2015-03-12 | -$9.08M 10-Q · filed 2014-08-12 | -$13.24M derived: sum of 3 quarters · filed 2015-03-12 | -$17.35M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | -$3.55M 10-K · filed 2015-03-12 | -$7.70M derived: sum of 2 quarters · filed 2015-03-12 | -$11.82M derived: sum of 3 quarters · filed 2015-03-12 | -$14.55M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2012-12-31 | -$4.16M 10-K · filed 2014-03-17 | -$8.27M derived: sum of 2 quarters · filed 2014-03-17 | -$11.01M derived: sum of 3 quarters · filed 2014-03-17 | -$14.24M 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | -$4.11M 10-K · filed 2014-03-17 | -$6.85M derived: sum of 2 quarters · filed 2014-03-17 | -$10.08M 10-Q · filed 2013-11-13 | |||||
| 2012-06-30 | -$2.74M 10-K · filed 2014-03-17 | -$5.97M derived: sum of 2 quarters · filed 2014-03-17 | ||||||
| 2012-03-31 | -$3.23M 10-K · filed 2014-03-17 | |||||||
| 2011-12-31 | -$13.43M 10-K · filed 2014-03-17 | |||||||
| 2010-12-31 | -$16.22M 10-K · filed 2014-03-17 | |||||||
| 2009-12-31 | -$13.33M 10-K · filed 2014-03-17 | |||||||
| 2008-12-31 | -$7.17M 10-K · filed 2014-03-17 | |||||||
| 2007-12-31 | -$1.22M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |